Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Pyxis Oncology Inc PYXS

Healthcare Biotechnology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product... see more

Recent & Breaking News (NDAQ:PYXS)

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire March 23, 2026

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

GlobeNewswire February 3, 2026

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire December 18, 2025

Pyxis Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire November 3, 2025

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire November 3, 2025

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

GlobeNewswire October 13, 2025

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

GlobeNewswire October 9, 2025

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 30, 2025

Pyxis Oncology to Participate in September Investor and Industry Conferences

GlobeNewswire August 21, 2025

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 14, 2025

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 30, 2025

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 15, 2025

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 14, 2025

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

GlobeNewswire April 25, 2025

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

GlobeNewswire April 2, 2025

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

GlobeNewswire March 25, 2025

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 18, 2025

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

GlobeNewswire March 3, 2025

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

GlobeNewswire February 26, 2025

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

GlobeNewswire February 4, 2025

Podcasts